While Mannkind Corp has overperformed by 4.53%, investors are advised to look at stock chart patterns for technical insight. Within its last year performance, MNKD fell by -13.84%, with highs and lows ranging from $7.63 to $3.38, whereas the simple moving average jumped by 15.53% in the last 200 days.
On October 20, 2025, Wells Fargo started tracking Mannkind Corp (NASDAQ: MNKD) recommending Overweight. A report published by Leerink Partners on October 10, 2025, Initiated its previous ‘Outperform’ rating for MNKD. H.C. Wainwright also rated MNKD shares as ‘Buy’, setting a target price of $9 on the company’s shares in an initiating report dated July 16, 2025. Mizuho Initiated an Outperform rating on April 10, 2025, and assigned a price target of $12. Wedbush initiated its ‘Outperform’ rating for MNKD, as published in its report on February 10, 2025. Wells Fargo’s report from December 20, 2024 suggests a price prediction of $9 for MNKD shares, giving the stock a ‘Overweight’ rating. RBC Capital Mkts also rated the stock as ‘Outperform’.
Analysis of Mannkind Corp (MNKD)
Further, the quarter-over-quarter increase in sales is 5.72%, showing a positive trend in the upcoming months.
To gain a thorough understanding of Mannkind Corp’s future performance, several well-rounded types of analysis and research techniques can be used, with equity being among the most crucial. Taking into account the quick ratio of the company, currently set at 2.24, you can see that the company can cover any debts it may have, which can easily be seen in the annual report of the company.
It is also very valuable to look at average volume as an indicator of volatility for a stock, and MNKD is recording an average volume of 4.56M. On a monthly basis, the volatility of the stock is set at 4.97%, whereas on a weekly basis, it is put at 4.55%, with a gain of 0.18% over the past seven days. Furthermore, long-term investors anticipate a median target price of $10.38, showing growth from the present price of $5.54, which can serve as yet another indication of whether MNKD is worth investing in or should be passed over.
How Do You Analyze Mannkind Corp Shares?
A leading company in the Biotechnology sector, Mannkind Corp (MNKD) is based in the USA. When comparing Mannkind Corp shares with other companies under Healthcare, the P/E value is an influential factor to note. This is because it represents an indication of the future growth of the company in terms of investors’ expectations. Ultimately, the value of the latter should demonstrate steady, rapid growth, which is an accurate measure of the company’s progress. In addition to the value of 50.69, there is a growth in quarterly earnings of 128.38%.
The number of employees owning shares of the company should also be considered in addition to the fundamentals. This is because the values should be in line with investors’ expectations. As such, the current holdings of company stock inside the company are set at 2.87%. This can enable you to see the extent to which executives own the company’s stock. As opposed to executive stock, institutional ownership accounts for 55.60% of the company’s shares, contributing to an indication of company value, since large shareholders may signify strength within the organization.
